Tag: PD-1 inhibitor for uterine cancer

Home / PD-1 inhibitor for uterine cancer

Categories

Pembrolizumab with chemotherapy is approved by the USFDA for primary advanced or recurrent endometrial carcinoma

  June 2024: Pembrolizumab (Keytruda, Merck) has been authorized by the Food and Drug Administration for the treatment of adult patients with primary, advanced, or recurrent endometrial cancer...
pd-1-inhibitor-for-uterine-cancer

Scan the code